In contrast to MYBPC3, the pathogenic involvement of skeletal MyBP-C mutations was only recently revealed when MYBPC1 mutations were found in patients with the congenital muscle diseases DA and LCCS. This evidence concerns the gene MYBPC2 and lethal congenital contracture syndrome.